Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)-Reference-Cited by-同舟云学术

Drug‐Drug Interactions With the Hepatitis B Virus Capsid Assembly Modulator JNJ‐56136379 (Bersacapavir)

Published:2022-09-05 Issue:12 Volume:11 Page:1419-1429
ISSN:2160-763X
Container-title:Clinical Pharmacology in Drug Development
language:en
Short-container-title:Clinical Pharm in Drug Dev

Author:

Vandenbossche Joris¹,Yogaratnam Jeysen²,Hillewaert Vera¹,Rasschaert Freya¹,Talloen Willem¹,Biewenga Jeike¹,Snoeys Jan¹,Kakuda Thomas N.²,Palmer Martyn³,Nangosyah Julius¹,Biermer Michael¹

Affiliation:

1. Janssen Pharmaceutica NV Beerse Belgium

2. Janssen Research & Development South San Francisco California USA

3. Janssen Research & Development Spring House Pennsylvania USA

Funder

Janssen Research and Development

Publisher

Wiley

Subject

Pharmacology (medical),Pharmaceutical Science

Link

https://onlinelibrary.wiley.com/doi/pdf/10.1002/cpdd.1164

Reference13 articles.

1. Virology analysis of chronic hepatitis B virus–infected patients treated for 28 days with JNJ‐56136379 monotherapy

2. Anti-HBV activity of the HBV capsid assembly modulator JNJ-56136379 across full-length genotype A–H clinical isolates and core site-directed mutants in vitro

3. Antiviral Properties and Mechanism of Action Studies of the Hepatitis B Virus Capsid Assembly Modulator JNJ-56136379

4. Pharmacokinetics, Safety and Tolerability of JNJ-56136379, a Novel Hepatitis B Virus Capsid Assembly Modulator, in Healthy Subjects

5. JNJ-56136379, an HBV Capsid Assembly Modulator, Is Well-Tolerated and Has Antiviral Activity in a Phase 1 Study of Patients With Chronic Infection

Cited by 3 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. An open‐label study to explore the optimal design of CYP3A drug–drug interaction clinical trials in healthy Chinese people;Pharmacology Research & Perspectives;2024-07-28

2. The premise of capsid assembly modulators towards eliminating HBV persistence;Expert Opinion on Drug Discovery;2023-07-30

3. Pharmacokinetics of JNJ‐73763989 and JNJ‐56136379 (Bersacapavir) in Participants With Moderate Hepatic Impairment;The Journal of Clinical Pharmacology;2023-03-20